KNSA Q2 record revenue growth; 2026 guidance increased
Q2 delivered record revenue growth and the company increased 2026 guidance. ARCALYST reached 21% penetration in its core patient group, while pipeline assets including KPL-387 advanced.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.